Insilico Medicine used artificial intelligence to develop rentosertib, a drug for chronic lung disease, and early trial data suggests it may also reduce biological markers of aging. The findings come with major caveats: the sample size was small, the drug hasn't been tested in healthy people, and the "aging clocks" used to measure results are scientifically debated.

• Rentosertib reduced biological aging markers across six different AI-based "aging clocks" in a clinical trial, according to results published in Nature Biotechnology.
• The drug was originally developed for idiopathic pulmonary fibrosis (IPF) and has only been tested in sick patients, not healthy ones, so anti-aging claims remain speculative.
• The study has significant limitations: small sample size, unproven reliability of aging clock measurements, and the drug is still years away from regulatory approval even for its primary lung disease indication.

The article argues that AI will revolutionize drug discovery long before it can streamline clinical development, creating an abundance of candidate molecules but leaving patient trials as the main constraint. As discovery becomes commoditized and more assets target the same biology, real value will hinge on predictive toxicity, clinical efficacy, and strategic trial design.

• Drug candidate pipelines have doubled in the past decade but novel FDA approvals stayed flat at ~50/year, proving clinical development—not discovery—is the real bottleneck.
• Preclinical assets license for tens of millions, but value jumps to hundreds of millions or low-billions post-Phase 2 proof of concept—a premium set to shrink as AI floods the pipeline with candidates.
• Competition per target is already intense (100+ programs on targets like PD-1/GLP-1) and could double or triple by 2030, making individual molecules less rare and pushing investors to demand better translational data and trial design.
• AI excels at data-rich, fast-feedback problems (virtual screening, protein folding) but struggles with messy, high-variability clinical questions (endpoint selection, immune response prediction, adaptive trials)—so real value will shift to whoever masters those still-slow areas.

The article shows U.S. office visits remain at about 70% of pre-pandemic levels, driving high vacancy rates and a flight to newer buildings. It also highlights research linking remote work—not AI—to rising youth unemployment, explores AI uptake among small employer firms versus solopreneurs, and details how emerging biotechs now lead in clinical trials and drug approvals.

• Office visits are stuck at ~70% of pre-COVID levels, pushing vacancy above 14% (a post-2008 high), with tenants flocking to newer (post-2015) buildings while older ones bleed occupants.
• Young workers' higher unemployment traces to remote-work-friendly jobs, not AI exposure—a gap that predates AI's rise, per NY Fed research.
• AI adoption is highest among small firms with employees (26%) versus solo non-employer businesses (14-19%), though high-revenue solopreneurs are the biggest AI power users.
• Emerging pre-commercial biotechs have sharply increased their share of Phase I-III clinical trials over the past decade, cutting into big pharma's former dominance.

Anthropic cut off access to its Mythos 5 and Fable 5 AI models to comply with new US export controls. Elon Musk became the world’s first trillionaire after SpaceX shares surged in its IPO. The update also covers a CRISPR method that targets “undruggable” cancers and the first working nuclear clocks from Chinese and European teams.

• Anthropic fully cut off its Mythos 5 and Fable 5 models to comply with new US export controls barring their use outside the US.
• Elon Musk became the first trillionaire after SpaceX's IPO share price hit $135, pushing his net worth past $1 trillion—over 3% of US GDP.
• A new CRISPR method targets and destroys cells with a tumor-suppressor mutation found in up to half of all cancers (70-90% of hard-to-treat cases), offering a faster path to treatment than small-molecule drugs.
• Chinese and European teams each independently built working nuclear clocks using thorium-229, solving the laser wavelength problem with different approaches (higher power vs. denser crystal matrix).

Today’s TLDR rundown covers SpaceX’s IPO oversubscribed by more than four times, OpenAI prepping steep token-price cuts ahead of an AI price war with Anthropic, and Stack Overflow’s new API-first knowledge platform for AI agents. Plus quick briefs on gene-therapy vision reversal and China’s first commercial brain implant.

• SpaceX's IPO was oversubscribed more than 4x, selling 555.6M shares at $135 each—set to be the biggest IPO in U.S. history if it holds
• OpenAI is preparing to cut token prices to match Anthropic, risking thinner margins for both as they burn cash on GPU costs
• Stack Overflow launched an API-first "Stack Overflow for Agents" platform using multi-agent loops and trust scores to keep docs accurate for AI agents
• China approved NeuraMatrix's NEO brain-computer interface for commercial use, putting it ahead of Neuralink's N1, which remains stuck in U.S. research trials

10x Science built a platform that uses chemistry-based algorithms and AI agents to interpret complex mass spectrometry data, speeding up protein characterization for drug development. Backed by a $4.8 million seed round, it helps biotechs and pharma quickly validate AI-generated treatment candidates. The startup plans to refine its models and expand offerings by integrating broader cellular data.

• 10x Science raised a $4.8M seed round led by Initialized Capital to build AI that interprets mass spectrometry data for drug candidate validation, addressing the bottleneck created by AI protein-folding tools flooding pipelines with candidates.
• Its platform is fully traceable rather than a black box, which matters for regulatory compliance—unlike prior tools that over-promised or failed on complex molecules.
• Early users like Rilas Technologies report it shaves weeks off workflows, with the AI accurately identifying proteins by name and pulling sequences from public databases.
• Long-term plan is to layer cellular data on top of protein structure to create "molecular intelligence," positioning it as a potential go-to analytics engine for AI-driven drug development.

AWS introduced Amazon Bio Discovery, an AI-driven platform that lets researchers run complex drug-design workflows without coding. It provides a library of biological foundation models, an AI agent for workflow setup and analysis, and links to lab partners for synthesis and testing, cutting months of work down to weeks.

• AWS launched Amazon Bio Discovery, a no-code AI platform letting scientists run drug-design workflows using foundation models plus an AI agent, cutting months of research into weeks.
• In a Memorial Sloan Kettering/Twist Bioscience collaboration, nearly 300,000 AI-designed antibodies were narrowed to 100,000 for physical lab testing.
• Bayer, Broad Institute and Voyager Therapeutics are early adopters, and 19 of the top 20 global pharma companies already use AWS cloud services.
• AWS is separately partnering with Boston Consulting Group and Merck on an AI tool to improve clinical trial site selection.

Three MIT PhD students reverse-engineered Google's AlphaFold 3, creating Boltz-1 as an open-source alternative for drug discovery. Their platform enables pharmaceutical companies to conduct rapid and cost-effective drug-binding predictions while maintaining free access to the underlying models. Boltz aims to challenge commercial restrictions and offer a more accessible solution within the competitive landscape of AI in drug discovery.

• Three MIT PhD students reverse-engineered AlphaFold 3's methodology and released it as open-source Boltz-1, bypassing Google's restrictive licensing.
• Pharmaceutical companies can now run drug-binding predictions rapidly and cheaply without paying for or being restricted by Google's commercial terms.
• The project directly challenges the trend of AI drug-discovery tools being locked behind corporate control, pushing the field back toward open access.

Boltz is launching a transformative approach to drug design and biological research by combining AI and open science, enabling over 100,000 scientists to innovate faster. With a newly raised $28 million seed round and a partnership with Pfizer, Boltz aims to break down barriers in drug development through open-source models and accessible computational tools.

• Boltz raised a $28 million seed round and partnered with Pfizer to advance open-source drug design models.
• Over 100,000 scientists are already using Boltz's tools, positioning it as a widely-adopted open-science alternative to closed AI drug discovery platforms.
• The core bet is that open-source, freely accessible AI models can accelerate biological research and drug development faster than proprietary approaches.